FIELD: medicine.
SUBSTANCE: group of inventions relates to oncology, and is intended to reduce the size of a tumor and/or increase the survival rate of an oncological patient. The pharmaceutical combination contains a recombinant modified vaccinia virus Ankara (MVA) and an antibody. In another embodiment, a method for reducing tumor size and/or improving survival of a cancer patient is provided, comprising administering said pharmaceutical combination to the patient.
EFFECT: use of the group of inventions provides a reduction in tumor volume and/or an increase in the survival of a cancer patient due to the effective targeting and destruction of tumor cells.
32 cl, 33 dwg, 3 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2753882C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2798348C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
